Hello! Welcome to ONTORES!

CN +86-21-68388652

Your shopping cart is empty.

According to the order.

Ordering Center

Biological activity and in vivo tissue targeting distribution of Catesbeianlectin

Published: 2016-12-19

Keyword:

Article from our customer: Zhu Lin. Chin J Vet Sci. 2016.

Background: Peptide lectin is a biologically active molecule, which can agglutinate with red blood cells and bind to glycoproteins or sugar chains specifically. Recently, it has been used as a drug carrier.Peptide lectin can stablize drugs, increase the drug loading capacity, and reducing non-specific binding. Therefore, it is known as the second generation of bio-adhesive materials. In this study, a lectin was isolated from the bullfrog. The biological activity and the distribution in mice of this lectin were analyzed.

Results: Catesbeianlectin was screened from the cDNA library of Rana Catesbeiana skin, with the molecular of 1,465.8 kD, which is the smallest known lectin. Catesbeianlectin could cause strong agglutination of red blood cells and pathogenic bacteriainvitro. To determine the distribution in vivo, catesbeianlectin was labeled with 125I.Thelabeling efficiencywas 97.3%,and the radiochemical purity was 99.3%.Catesbeianlectin possesses good stability and ideal distribution in vivo and in vitro. When administrated by tail vein injection,125I-lectin was accumulated in liver, spleen and lung, and was metabolized predominantly by liver. When administrated by means of intragastric administration and intraperitoneal injection,125I-lectin was accumulated in stomach and spleen, and was metabolized predominantly by stomach. Furthermore, 125I-lectin cannot pass through the blood brain barrier.

Conclusion: Intravenous injection is a better way of administration of catesbeianlectin. This study demonstrated that catesbeianlectin can be potentially used as a drug carrier.


Fig 6 Isotope imaging of mice administrated with 125I-lectin via (A)tail vein injection, (B)intragastric administration and (C)intraperitoneal injection.

Catesbeianlectin was synthesized according to the standard solid phase peptide synthesisby ZheJiang Ontores Biotechnologies Co. Ltd. (Hangzhou, China). It was desalted and purified by the HPLC (waters 600 controller) reversed phase C18 column chromatography. The relative molecular mass was determined by the fast atom bombardment mass spectrometry (AB3200). The purity was ≥95%.